Table 3.
Body weight (kg) | Formulation | od dose | bid dose | tid dose | Total daily dose | |
---|---|---|---|---|---|---|
Min | Max | |||||
2.6 | < 3 | Oral suspension | 0.8 mg | 2.4 mg | ||
3 | < 4 | Oral suspension | 0.9 mg | 2.7 mg | ||
4 | < 5 | Oral suspension | 1.4 mg | 4.2 mg | ||
5 | < 6 | Oral suspension | 1.6 mg | 4.8 mg | ||
6 | < 7 | Oral suspension | 1.6 mg | 4.8 mg | ||
7 | < 8 | Oral suspension | 1.8 mg | 5.4 mg | ||
8 | < 9 | Oral suspension | 2.4 mg | 7.2 mg | ||
9 | < 10 | Oral suspension | 2.8 mg | 8.4 mg | ||
10 | < 12 | Oral suspension | 3.0 mg | 9 mg | ||
12 | < 20 | Oral suspension | 5 mg | 10 mg | ||
20 | < 30 | Tablet/oral suspension | 5 mg | 10 mg | ||
30 | < 50 | Tablet/oral suspension | 15 mg | 15 mg | ||
≥ 50 | Tablet/oral suspension | 20 mg | 20 mg |
aDosing regimen, including dosing frequency, will be adjusted if the child’s body weight changes during the study. †This dosing schedule may be subject to changes based on the results of the EINSTEIN-Jr phase III study; therefore, this dosing schedule cannot be used for the treatment of children with venous thrombosis outside the framework of the study
bid twice-daily, od once-daily, tid three-times-daily